Combivir and Haematotoxicity - a phase IV clinical study of FDA data

Summary:

Haematotoxicity is reported as a side effect among people who take Combivir (lamivudine; zidovudine), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Norvir, and have Hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Haematotoxicity when taking Combivir. It is created by eHealthMe based on reports of 15,371 people who have side effects when taking Combivir from the FDA, and is updated regularly.

What is Combivir?

Combivir has active ingredients of lamivudine; zidovudine. It is often used in hiv infection. eHealthMe is studying from 15,450 Combivir users. Check the latest studies of Combivir.

What is Haematotoxicity?

Haematotoxicity (toxins that destroy red blood cells) is found to be associated with 343 drugs and 830 conditions by eHealthMe. Check the latest studies of Haematotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

15,371 people reported to have side effects when taking Combivir.
Among them, 13 people (0.08%) have Haematotoxicity.

Among these 13 people:

How long have people been on Combivir when they have Haematotoxicity? *

What is the gender of people who have Haematotoxicity when taking Combivir? *

female: 15.38 %
male: 84.62 %

What is the age of people who have Haematotoxicity when taking Combivir? *

What are other drugs people take besides Combivir? *

What are other side effects people have besides Haematotoxicity? *

Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 4 people, 30.77%
Drug Rash With Eosinophilia And Systemic Symptoms (adverse drug reactions with rash): 3 people, 23.08%
Immune System Disorder: 3 people, 23.08%
Drug Resistance (reduction in effectiveness of a drug): 3 people, 23.08%
Heart Disease: 2 people, 15.38%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 2 people, 15.38%
Skin Disorder (skin disease): 2 people, 15.38%
Death: 2 people, 15.38%
Anaemia Megaloblastic (disorder of abnormally large red blood cells): 1 person, 7.69%
Bone Marrow Depression (decreased ability or inability of the bone marrow to produce blood cells): 1 person, 7.69%

What are the existing conditions these people have? *

Toxoplasma Serology Positive: 1 person, 7.69%
Hodgkin's Lymphoma (cancer originating from white blood cells): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Combivir and have Haematotoxicity?

- Check whether Haematotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Combivir:

Combivir (15,450 reports)

Haematotoxicity treatments and more:

Haematotoxicity (8,984 reports)

Browse all side effects of Combivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematotoxicity:

Haematotoxicity (343 drugs)

Browse all the conditions that are associated with Haematotoxicity:

Haematotoxicity (830 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine; zidovudine (the active ingredients of Combivir) and Combivir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.